A phase II study investigating safety and efficacy of dose reduced fludarabine, cyclophosphamide and obinutuzumab versus chlorambucil and obinutuzumab in untreated, comorbid, elderly patients with chronic lymphocytic leukemia (CLL)

被引：0
|
作者：
Mulligan, Stephen [1 ,2 ]
Tam, Constantine [1 ,2 ]
Badoux, Xavier [1 ,2 ]
Kuss, Bryone [1 ,2 ]
机构：
[1] Australasian Leukaemia & Lymphoma Grp, Richmond, VI, Australia
[2] CLL Australian Res Consortium, Richmond, VI, Australia
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [41] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
    Jain, Nitin
    Thompson, Philip
    Burger, Jan
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Estrov, Zeev
    Borthakur, Gautam
    Bose, Prithviraj
    Kadia, Tapan
    Pemmaraju, Naveen
    Sasaki, Koji
    Konopleva, Marina
    Jabbour, Elias
    Garg, Naveen
    Wang, Xuemei
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey
    Wang, Sa
    Lopez, Wanda
    Ayala, Ana
    Plunkett, William
    Gandhi, Varsha
    Kantarjian, Hagop
    O'Brien, Susan
    Keating, Michael
    Wierda, William G.
    LEUKEMIA, 2021, 35 (12) : 3421 - 3429
  • [42] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del(17p)
    Jain, Nitin
    Thompson, Philip
    Burger, Jan A.
    Borthakur, Gautam
    Bose, Prithviraj
    Estrov, Zeev
    Ferrajoli, Alessandra
    Gandhi, Varsha
    Plunkett, William
    Lopez, Wanda
    Kantarjian, Hagop
    O'Brien, Susan
    Keating, Michael
    Wierda, William
    LEUKEMIA & LYMPHOMA, 2017, 58 : 158 - 159
  • [43] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p).
    Jain, Nitin
    Thompson, Philip A.
    Burger, Jan Andreas
    Borthakur, Gautam
    Bose, Prithviraj
    Estrov, Zeev
    Ferrajoli, Alessandra
    Gandhi, Varsha
    Plunkett, William
    Lopez, Wanda
    Kantarjian, Hagop M.
    O'Brien, Susan Mary
    Keating, Michael J.
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)
    Jain, N.
    Thompson, P.
    Burger, J.
    Borthakur, G.
    Bose, P.
    Estrov, Z.
    Ferrajoli, A.
    Gandhi, V.
    Plunkett, W.
    Lopez, W.
    Kantarjian, H.
    O'Brien, S.
    Keating, M.
    Wierda, W.
    HAEMATOLOGICA, 2017, 102 : 171 - 171
  • [45] Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia
    Sharman, Jeff P.
    Burke, John M.
    Yimer, Habte A.
    Boxer, Michael A.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Danilov, Alexey V.
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 791 - 800
  • [46] Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
    Davids, Matthew S.
    Lampson, Benjamin L.
    Tyekucheva, Svitlana
    Crombie, Jennifer L.
    Ng, Samuel
    Kim, Austin I.
    Weinstock, Matthew
    Lowney, Jessica
    Pazienza, Samantha
    Montegaard, Josie
    Patterson, Victoria
    Jacobson, Caron A.
    LaCasce, Ann S.
    Armand, Philippe
    Arnason, Jon E.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2020, 136
  • [47] Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study
    Takizawa, Jun
    Teshima, Takanori
    Ennishi, Daisuke
    Ichikawa, Satoshi
    Suzuki, Ritsuro
    Kojima, Akira
    Takahashi, Yusuke
    Hayashi, Nobuya
    Kawasumi, Hisashi
    Murayama, Kosho
    Cheung, Patricia
    Kawata, Toshio
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1586 - 1594
  • [48] An updated survival analysis from the CLL11 study in patients with chronic lymphocytic leukaemia treated with obinutuzumab or rituximab in combination with chlorambucil versus chlorambucil alone
    Follows, G.
    Fischer, K.
    Bosch, F.
    Frederiksen, H.
    Cuneo, A.
    Ludwig, H.
    Crompton, N.
    Maurer, J.
    Uguen, M.
    Fingerle-Rowson, G.
    Hallek, M.
    Goede, V.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 95 - 95
  • [49] Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia
    Sharman, Jeff P.
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Pagel, John M.
    Flinn, Ian W.
    Kamdar, Manali
    Munir, Talha
    Walewska, Renata
    Corbett, Gillian
    Fogliatto, Laura Maria
    Herishanu, Yair
    Banerji, Versha
    Coutre, Steven
    Follows, George
    Walker, Patricia
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Cymbalista, Florence
    Woyach, Jennifer A.
    Ferrant, Emmanuelle
    Wierda, William G.
    Munugalavadla, Veerendra
    Yu, Ting
    Wang, Min Hui
    Byrd, John C.
    LEUKEMIA, 2022, 36 (04) : 1171 - 1175
  • [50] Fludarabine vs high dose continuous chlorambucil: Interim analysis of a randomized phase II study in untreated B-cell chronic lymphocytic leukemia (B-CLL).
    Jaksic, B
    Delmer, A
    Brugiatelli, M
    Suciu, S
    Baumelou, E
    Roozendaal, KJ
    Wijermans, PW
    Jehn, U
    Teixeira, A
    Peeters, E
    Solbu, G
    Zittoun, R
    Willemze, R
    BLOOD, 1996, 88 (10) : 2342 - 2342
12345